Another option to target AML involves treatments that disrupt the microenvironment in which the malignant cells reside, e.g., uproleselan is a selective antagonist of the adhesion molecule, E-Selectin [72, 73]. This evidence concerns the gene SELE and acute myeloid leukemia.